Biggest News Aggregation in the World
📰 Ophthalmic Solution News

Page 2 - Ophthalmic Solution News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Ophthalmic Solution. Real-time updates on events, politics, business and more.

Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Therapeutics

/PRNewswire/ -- DelveInsights Myopia Market Insights report includes a comprehensive understanding of current treatment practices, myopia emerging drugs,...
Shruti Thakur Cellix Bio Prnewswire Delveinsight Laboratorios Sophia Essilor International Sightglass Vision Inc

Alembic, Aurobindo recall drugs in US market

Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to...
New Delhi United States Aurobindo Pharma Drug Administration Alembic Pharmaceuticals Aurobindo Pharma United States Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Lupin gets USFDA nod for Bromfenac Ophthalmic Solution

Pharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who have undergone cataract surgery. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bromfenac Ophthalmic Solution 0.09 per cent, Lupin said in a regulatory filing.
Madhya Pradesh Drug Administration Bromfenac Ophthalmic Solution Bromday Ophthalmic Solution Ophthalmic Solution Us Food And Drug Administration

Why Aldeyra Therapeutics Stock Is Trading Higher Today

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The trial achieved statistical significance for the primary endpoint and all secondary endpoints. Also Read: Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients. Relative to patients treated with vehicle, patients treated with reproxalap reported statistica
Aldeyra Therapeutics Inc Aldeyra Highlights New Drug Application Benzinga Pro Allergic Conjunctivitis Primary Endpoint
Source: yahoo.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science